TP53 and cancer: Thus, the selective checkpoint response, cell cycle inhibition and cytotoxicity induced by RRP15-dependent nucleolar stress in p53-proficient non-transformed cells and p53-deficient tumor cells suggest that RRP15 might be a potential target for cancer therapy.